Search Clinical Trials

3 Results

Active, Not Recruiting
Post IVIG Medication in Children With Immune Thrombocytopenia (External Link)
Immune thrombocytopenia (ITP) is the most common acquired immune cytopenia in childhood, affecting 4-6 in 100,000 children. The pathophysiology of ITP is highly complex and incompletely understood. Accepted mechanisms include …
Baylor Role: Lead Sponsor
Active, Not Recruiting
Eltrombopag vs Standard Front Line Management for Newly Diagnosed Immune Thrombocytopenia (ITP) in Children (External Link)
This is a prospective, open label, randomized, two-arm, multi-center Phase 3 trial. Patients with newly diagnosed ITP are randomized 2:1 to receive the experimental treatment, eltrombopag, or investigator's choice of …
Baylor Role: Lead Sponsor
Completed
Association of Platelet Parameters With Bleeding Severity in Children With ITP (External Link)
Many children with severe immune thrombocytopenia (ITP) present with mild symptoms and their disease spontaneously resolves within 3 to 6 months. However, a subset of pediatric ITP patients experience severe …
Baylor Role: Collaborator